research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
Search
for
Sort by
Research
600-630 / 1000+ resultsresearch Anti-TNF-Alpha Induced Psoriasiform Eruptions with Severe Scalp Involvement and Alopecia: Report of Five Cases and Review of the Literature
Severe anti-TNF-α induced scalp eruptions often need stopping the drug and using systemic therapy to avoid scarring.
research Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series
Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.
research Periocular pigmentation associated with use of travoprost for the treatment of alopecia areata of the eyelashes
Travoprost can help eyelash growth but may cause darkening around the eyes.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
research Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
research From Eye Care to Hair Growth: Bimatoprost
Bimatoprost helps with hair growth and eye conditions but can be costly and have side effects.
research Other Products Being Developed by Pharmaceutical and Cosmetic Companies
Minoxidil can cause hair growth as a side effect.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Ottawa, Ontario, Canada, February 13–16, 2013
The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
research Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women
Some skin medications are safe for pregnant women, but others pose risks or should not be used.
research Acute Granulomatous Interstitial Nephritis Post-COVID-19 Vaccination
COVID-19 vaccination may cause kidney inflammation, treatable with steroids and Cellcept.
research Kerion Type of Tinea Capitis Treated with Double Pulse Dose Terbinafine
Double pulse dose terbinafine effectively treats kerion type of tinea capitis.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Effect of minoxidil on rabbit lens epithelial cell behavior in vitro and in situ
Minoxidil may help prevent capsular opacification after cataract surgery.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Improvement of Satoyoshi syndrome with tacrolimus and corticosteroids
Tacrolimus and corticosteroids can improve symptoms of Satoyoshi syndrome.
research Comparative efficacy of topical anthralin and intralesional triamcinolone in the treatment of alopecia areata.
Triamcinolone regrows hair better but relapses more than anthralin.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research Therapeutic Effect of Superficial Cryotherapy versus Intralesional Corticosteroids injection in Alopecia Areata
TCA injections are more effective and safer than cryotherapy for treating alopecia areata.
research [Oral treatment of severe psoriasis with a new aromatic retinoid (Ro 10-9359) (author's transl)].
Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
research Evaluation Of The Use Of Cyclophosphamide In Children Diagnosed With Steroid Resistant Nephrotic Syndrome Treated In The 3rd Floor Treatment At Fatmawati Hospital
Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: a comparative study
Platelet rich plasma is as effective as triamcinolone for treating alopecia areata.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Peritoneal reactions with some of the tubal occlusive agents.
GRF is not safe for tubal occlusion.